Announced that its proprietary antibody today.

Clivatuzumab tetraxetan displays promising results in patients with metastatic pancreatic cancer Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other significant diseases, announced that its proprietary antibody today, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine continues to create promising efficacy results in individuals with previously untreated, inoperable, locally advanced or metastatic pancreatic cancer. At the 2010 American Culture of Clinical Oncology annual conference, Dr sildenafil citrate drug .

crmedicaltourism.com

Clinicans warned about randomized clinical trials A review content in the November 2 problem of JAMA: The Journal of the American Medical Association, suggests clinicians must view with skepticism the total results of randomized clinical trials stopped early because of apparent benefit. Victor M. Montori, M.D., M.Sc., from McMaster University, Hamilton, Ontario, and colleagues conducted a review of the medical literature to identify randomized medical trials of any intervention reported simply because having been stopped earlier than planned because of outcomes favoring the experimental intervention. ‘Of 143 RCTs stopped early for benefit, the majority were released in 5 high-impact medical journals.